Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.0)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 2, March-April, p. 303–308

doi: 10.17219/acem/44372

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Prevalence of Helicobacter pylori Infection in Symptomatic Children: A 13-Year Observational Study in the Lower Silesian Region

Monika M. Biernat1,A,C,D, Barbara Iwańczak2,B, Aldona Bińkowska1,C, Joanna Grabińska1,B, Grażyna Gościniak1,E,F

1 Department of Microbiology, Wroclaw Medical University, Poland

2 Department of Pediatric Gastroenterology and Nutrition, Wroclaw Medical University, Poland

Abstract

Background. Helicobacter pylori (H. pylori) infection is very common worldwide, with varying frequency. According to data from epidemiological reports, a third of the population of children in Poland are infected with H. pylori before the age of 18. In recent years, a decrease in the incidence of H. pylori infection in both children and adults has been observed in many countries.
Objectives. The aim of the study was to assess the prevalence H. pylori and non-helicobacter pylori helicobacter (NHPH) infection in symptomatic children from 2000 to 2013, and to analyze the resistance of H. pylori strains to antibiotics over the 13-year study period.
Material and Methods. The retrospective analysis was based on the results of cultures for H. pylori in 8661 untreated children undergoing their first upper gastroduodenal endoscopy because of clinical symptoms such as chronic abdominal pain/distress, epigastric pain, nausea or vomiting. Drug sensitivity to three antibiotics – amoxicillin (AM), clarithromycin (CH) and metronidazole (MZ) – was determined by the gradient diffusion method (E-test).
Results. Overall, among 8661 cultures analyzed, 16.05% were positive for H. pylori. The highest prevalence of infection was found in the year 2000 (23.06%) and the lowest in the year 2010 (8.90%). The prevalence of NHPH infection was low (0.2%). A three-fold increase in the number of strains resistant to both CH and MZ was noted, from 7.9% to about 22.7%. All strains were susceptible to AM.
Conclusion. There has been a decline in the prevalence of H. pylori infection in symptomatic children, but this infection is still a common cause of upper gastrointestinal tract symptoms in children treated at the authors’ center. Primary antibiotic resistance of H. pylori increased over the period analyzed, but primary resistance to metronidazole declined.

Key words

antibiotic resistance, H. pylori, NHPH

References (31)

  1. Castillo-Rojas G, Cerbon MA, Lopez-Vidal Y: Presence of Helicobacter pylori in a Mexican Pre-Columbian Mummy. BMC Microbiology 2008, 8, 119. DOI: 10.1186/1471-2180-8-119.
  2. Warren JR, Marshall B: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, 1, 1273–1275.
  3. Peleteiro B, Bastos A, Ferro A, Lunet N: Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage. Dig Dis Sci 2014, 59, 8, 1698–1709.
  4. Łaszewicz W, Iwańczak F, Iwańczak B: Seroprevalence of Helicobacter pylori infection in Polish children and adults depending on socioeconomic status and living conditions. Adv Med Sci 2014, 59, 1, 147–150.
  5. Baele M, Pasmans F, Flahou B, Chiers K, Ducatelle R, Haesebrouck F: Non-Helicobacter pylori helicobacters detected in the stomach of humans comprise several naturally occurring Helicobacter species in animals. FEMS Immunol Med Microbiol 2009, 55, 3, 306–313.
  6. Flahou B, Haesebrouck F, Smet A, Yonezawa H, Osaki T, Kamiya S: Gastric and enterohepatic non-Helicobacter pylori helicobacters. Helicobacter 2013, 18, Suppl s, 66–72.
  7. Momtez H, Souod N, Dabiri H, Sarshar M: Study of Helicobacter pylori genotype status in saliva, dental plaques, stool and gastric biopsy samples. World J Gastroenterol 2012, 18, 2105–2111.
  8. Iwańczak B, Francavailla R: Helicobacter pylori infection in pediatrics. Helicobacter 2014, Suppl 1, 46–51. DOI: 10.1111/hel.12158.
  9. Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S, Chayama K: Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjectsfor gastric neoplasm. Helicobacter 2014, 19, 1–8. DOI: 10.1111/hel.12101. Epub 2013 Nov 11.
  10. Okuda M, Osaki T, Lin Y, Yonezawa H, Maekawa K, Kamiya S, Fukuda Y, Kikuchi S: Low prevalence and incidence of Helicobacter pylori infection in children: A population-based study in Japan. Helicobacter 2015, 20, 133–138. DOI: 10.1111/hel.12184. Epub 2014 Nov 8.
  11. Dixon MF, Genta RM, Yardley JH, Correa P, the participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol 1996, 20, 10, 1161–1181.
  12. Biernat MM, Poniewierka E, Błaszczuk J: Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland. Arch Med Sci 2013, 10, 3, 505–509.
  13. Glupczynski Y, Broutet N, Cantagrel A: Comparison of the E-test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002, 21, 7, 549–552.
  14. Megraud F, Lehours P: Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007, 20, 2, 280–322.
  15. Eusebi LH, Zagari RM, Bazzoli F: Epidemiology of Helicobacter pylori infection. Helicobacter 2014, Suppl 1, 1–5. DOI: 10.1111/hel.12165.
  16. Calvet X, Ramírez Lázaro M, Lehours JP, Mégraud F: Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013, 18, Suppl 1, 5–11.
  17. Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominquez RL, Cook P, Anderson G: Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013, 24, 2, 209–215.
  18. Duque X, Vilchis J, Mera R: Natural history of Helicobacter pylori infection in Mexican schoolchildren: incidence and spontaneous clearance. J Pediatr Gastroenterol Nutr 2012, 55, 2, 209–216.
  19. Iwańczak F, Gościniak G, Iwańczak B, Grabińska J: 10-years evaluation of the prevalence of Helicobacter pylori infection and assessment of resistance to metronidazole and clarithromycin in children. Gastroenterol Pol 2004, 11, 2, 141–146.
  20. Iwańczak F, Iwańczak B, Pytrus T, Dworak O, Gościniak G, Vogtt E: Prevalence of H. pylori infection in the Polish child population. Pol Merk Lek 2005, 18, 106, 407–411.
  21. Krusiec-Świdergoł B, Kwiecień J, Jonderko K, Strój L, Kasicka-Jonderko A, Błońska-Fajfrowska B: Decreasing prevalence of Helicobacter pylori infection in children in Poland. Prz Gastroenterol 2010, 5, 279–284.
  22. Czaja-Bulsa G, Gębala A, Matacz M, Tetera E: Helicobacter pylori infection in children from the Western Pomeranian Region. Prz Gastroenterol 2008, 3, 4, 196–200.
  23. Tkachenko MA, Zhannat NZ, Erman LV, Blashenkova EL, Isachenko SV, Isachenko OB, Graham DY, Malaty HM: Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: A 10-year follow-up study in Russia. J Ped Gastroenterol Nutr 2007, 45, 4, 428–432.
  24. Boyanova L, Lazarova E, Jelev C, Gergova G, Mitov I: Helicobacter pylori and Helicobacter heilmannii in untreated Bulgarian children over a period of 10 years. JMM 2007, 56, 8, 1081–1085.
  25. Ierardi E, Monno RA, Gentile A, Francavilla R, Burattini O, Marangi S, Pollice L, Francavilla A: Helicobacter heilmannii gastritis: A histological and immunohistochemical trait. J Clin Pathol 2001, 54, 10, 774–777.
  26. Iwańczak B, Biernat M, Iwańczak F, Grabińska J, Matusiewicz K, Gościniak G: The clinical aspects of Helicobacter heilmannii infection in children with dyspeptic symptoms. J Physiol Pharmacol 2012, 63, 2, 133–136.
  27. Gościniak G, Skala J, Kubiak K, Iwańczak B, Biernat M, Grabińska J: The role of environmental Helicobacter heilmannii infection in etiopathogenesis of gastric diseases. Gastroenterol Pol 2006, 13, 320–323.
  28. Duck WM, Sobel J: Antimicrobial resistance incidence and risk factors among Helicobacter pyloriinfected persons, United States. Emerg Infect Dis 2004, 10, 6, 1088–1094.
  29. Hunt RH, Xiao SD, Megraud F, LeonBarua L, Bazzoli F, Van der Merwe S, Vaz Coehlo LG, Fock M: Helicobacter pylori in developing countries. World Gastroenterology Organization Global Guideline. J Gastrointestin Liver Dis 2011, 20, 3, 299–304.
  30. Megraud F, Coenen S, Versporten A, Kist, M: Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotics consumption. Gut 2013, 62, 1, 34–42.
  31. Karczewska E, Wojtas-Bonior I, Sito E, Zwolińska-Wcisło EM, Budak A: Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011, 63, 3, 799–807.
© Wroclaw Medical University